secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-111285
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q3 revenue $20.7M (+9% YoY); upsizes credit facility to $70M with Perceptive
--------------------------------------------------------------------------------

- Q3 revenue $20.7M (+9% YoY); net loss $8.6M vs $10.4M year ago; operating loss $7.6M.
- Full-year 2025 revenue guidance revised to at least 16% growth over 2024.
- Closed $70M credit facility from Perceptive Advisors: $60M initial draw, $10M accordion; interest rate 7.85%+greater of Term SOFR or 4.25%, interest-only to Nov 2030.
- Appointed Betty Jo Rocchio and Bill Plovanic to the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925111285/0001104659-25-111285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925111285/tm2531116d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-111285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer